Cic edizioni internazionali
Clinical Dermatology

Clinical evaluation of AKBBA in the management of psoriasis

Original Article, 17 - 24
doi: 10.11138/cderm/2014.2.1.017
Tag this article
Abstract
Enhanced HTML Full text PDF
Introduction. Psoriasis is a common chronic inflammatory, immune-mediated disease that predominantly affects the skin and joints, characterized by circumscribed, red, thickened plaques with an overlying silver-white scale (1). Though many pharmaceutical drugs and biologics are available in the market, they have very less impact on the psoriatic patients due to their own and many limitations.
Therefore, as a complementary and alternative medicine (CAM), Boswellia serrata Roxb has been explored and found to be safe and efficient in the management of mild to moderate psoriasis.
Objective. In the current study, we aimed at investigating a cream of Boswellia serrata Roxb extract
standardized for 5% of 95% 3-O-Acetyl-11-Keto Beta Boswellic Acid (AKBBA) (in the form of a cream), for the management of mild to moderate chronic plaque Psoriasis.
Method. An open label, multi centred phase III clinical trial, evaluating 200 psoriatic patients with application of AKBBA cream thrice a day for a period of 12 weeks was carried out. Changes in ‘modified’ Psoriasis Activity Severity Index (PASI) & biomarkers (LTB4, TNF alpha, VEGF, PGE2) from the baseline values along with remissions in clinical lesions observed through photographic images were considered for efficacy evaluation.
Results. Highly significant changes in LTB4 (p<0.001) & TNF alpha (p<0.01) values from the baseline along with significant changes (p<0.05) in VEGF & PGE2 were observed. Reduction in ‘modified’ PASI score from the baseline visit was in consensus with the global evaluations by physician and patients.
Conclusion. We propose topical application of AKBBA cream, may be useful in the management of mild to moderate chronic plaque psoriasis.

Vol. 5 (No. 1) 2017 January - March

  1. Unmet needs in hidradenitis suppurativa: patients’ perspective on daily management and cosmetic cares
    Atzori L., Pintori G., Patta F., Pinn A.L., Rongioletti F.
    doi: 10.11138/cderm/2017.5.1.001
  2. EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro
    Umbert I., Sans G., Valls J., Márquez L., Costales P., Fernández L.
    doi: 10.11138/cderm/2017.5.1.005
  3. Cutaneous leishmaniasis and its clinical spectrum. An overview from the Old World
    Dassoni F.
    doi: 10.11138/cderm/2017.5.1.012
  4. Systemic immunosuppressive treatment in adult patients with atopic dermatitis: current and new treatment options
    van der Schaft J., Thijs J.L., Hijnen D., de Bruin-Weller M.S.
    doi: 10.11138/cderm/2017.5.1.022
  5. Possible role of mast cells and IL-37 in the pathogenesis of psoriasis
    Conti P., Caraffa A., Spinas E., Lessiani G., Kritas S.K., Ronconi G., Theoharides T.C.
    doi: 10.11138/cderm/2017.5.1.030
  6. Commentary on dermoscopy in general dermatology
    Russo T., Piccolo V., Agozzino M., Moscarella E., Lallas A., Argenziano G.
    doi: 10.11138/cderm/2017.5.1.037
  7. Gluten related disorders: even a dermatological issue
    Bonciolini V., Caproni M.
    doi: 10.11138/cderm/2017.5.1.043
  8. Congenital mastocytosis
    Virdi A., Neri I., Gurioli C., Patrizi A.
    doi: 10.11138/cderm/2017.5.1.048
  9. Frontal fibrosing alopecia: when the treatment is worse than the disease
    Lai M., Brundu M.A., Atzori L.
    doi: 10.11138/cderm/2017.5.1.060
Last Viewed articles: la lista degli ultimi x visitati.
  1. Clinical evaluation of AKBBA in the management of psoriasis
    Muhammed M., Nagabhushanam K., Sankaran N., Sood R., Karri S.K.
    doi: 10.11138/cderm/2014.2.1.017
credits